Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02583763
Other study ID # 2012/257-31
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 2013
Est. completion date December 2023

Study information

Verified date March 2021
Source University Hospital, Linkoeping
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim is to increase awareness of the relationship between (IUGR) and cardiac function in the foetus, the development of cardiac function over time after delivery and what significance a possible early disturbed myocardial function have for the neonate and the child during the first years of life.


Description:

This is a prospective case-control study in which fetuses from normal pregnancies will be compared with fetuses with IUGR. Parents will be asked to participate in the study in connection with the routine ultrasound examinations at the department of obstetrics to where they have been referred because of suspected IUGR. The control group will be randomly selected among pregnant women who come for routine ultrasound during pregnancy at gestational week 18-20. Surveys will be performed in the third trimester and after delivery. During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyses will be performed off-line and analysed by vector velocity imaging software. With this technique, the investigator can quantify the chamber wall and myocardial movements. Speed (velocity), movement (displacement) and thickening/deformation (strain and strain rate) will be recorded in a structured and standardized manner. When performing the analysis the heart's walls are outlined and the software extracts the movement in different directions. Data will be obtained concerning the participating mothers previous illness, mothers' age, maternal smoking, BMI, any abnormalities during pregnancy, number of previous pregnancies. Other data that will be recorded are means of delivery and any abnormalities during previous pregnancies, such as hypertension, preeclampsia and pre-natal steroid treatment. Additional data to be collected from the participating fetuses are flow profiles in the umbilical artery, ductus venosus and middle cerebral artery. Abdominal circumference and estimated weight will be registered. Following delivery, the participating child's height, weight, head circumference and gestational age at birth are registered. Additional data that will be collected after delivery are umbilical vein and umbilical artery acid base values, Apgar score. If admitted to the pediatric ward the investigators will register the number of days hospitalized in the ward for post-natal care and diagnosis. The investigators plan to examine the participating baby with cardiac ultrasound between 12 and 72 hours after delivery and again when the participating child is 3-4 months old and at 7 years of age. The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the participating children's DNA. Based on power calculation the investigators plan to examine between 20-30 fetuses with IUGR and 40-60 healthy fetuses in the control group.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Inclusion of research subjects: Growth restriction in routine pregnancy ultrasound, verified by specialist control. Gestational age based on Crown Rump Length measurements during the first trimester. Growth restriction defined by a deviation more than 22% from the normal curve at a given gestational age or growth rate deviates more than 10% compared to the previous measurement in relation to the expected weight. - Inclusion of controls: Control individuals recruited among mothers who come to routine pregnancy ultrasound control at gestational week 18. These are randomly selected and then asked to participate. Exclusion Criteria: - Exclusion of both the cases with IUGR and the control cases are major malformations, twin pregnancy, signs of intrauterine infection during pregnancy, significant illness or significant medical treatment of the mother.

Study Design


Intervention

Other:
Echocardiography
During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
Procedure:
Blood sample
The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.

Locations

Country Name City State
Sweden Dept of Obstetrics and Gynecology Linköping
Sweden Paediatric Department University Hospital Linköping

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Linkoeping Ostergotland County Council, Sweden, Stiftelsen Samariten

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Velocity of the cardiac walls Echocardiography images of the heart's walls are outlined and the software extracts the movement in different directions. At least two times before delivery from gestational age 28 weeks to delivery. Three times after delivery, 12-72 hours, 3-4 months and 7 years.
Secondary Displacement of the cardiac walls Echocardiography images of the heart's walls are outlined and the software extracts the movement in different directions. At least two times before delivery from gestational age 28 weeks to delivery. Three times after delivery, 12-72 hours, 3-4 months and 7 years.
Secondary Strain in the cardiac walls Echocardiography images of the heart's walls are outlined and the software extracts the movement in different directions. At least two times before delivery from gestational age 28 weeks to delivery. Three times after delivery, 12-72 hours, 3-4 months and 7 years.
Secondary Cardiac marker Troponin T Comparing cardiac marker troponin T between the two groups At birth and at 7 years of age
Secondary Cardiac marker N-terminal prohormone of brain natriuretic peptide (NT-ProBNP) Comparing cardiac marker NT-ProBNP between the two groups At birth and at 7 years of age
Secondary Insulin-like growth factor-1 (IGF-1) Comparing IGF-1 between the two groups At birth and at 7 years of age
Secondary Insulin-like growth factor binding protein (IGFBP) Comparing IGFBP between the two groups At birth and at 7 years of age
Secondary DNA methylation and gene expression in blood monocytes and lumfocytes Changes in DNA metylation will be compared between the two groups At birth and at 7 years of age
See also
  Status Clinical Trial Phase
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT04502823 - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler N/A
Not yet recruiting NCT03625518 - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes Early Phase 1
Completed NCT05176041 - SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A
Completed NCT01695070 - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Completed NCT04289350 - Day to Day Variation in Fetal Heart Rate Variability
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting NCT05023161 - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed NCT02590536 - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction Phase 3
Not yet recruiting NCT05029778 - Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve Phase 4
Recruiting NCT05576207 - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR) N/A
Active, not recruiting NCT05160649 - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed NCT02280031 - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Phase 2
Recruiting NCT04389099 - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting NCT06039319 - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting NCT05651347 - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction Phase 3
Recruiting NCT02336243 - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Phase 3
Active, not recruiting NCT01594463 - Routine Ultrasound Screening in the Third Trimester N/A